Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review

Acta Psychiatrica Scandinavica

Volumn 135, Issue 1, 2017, Pages 8-28

  Jobski, K ^a   Hofer J ^a   Hoffmann, F ^a   Bachmann, C ^b  

^a UNIVERSITY OF OLDENBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

autism spectrum disorder; drug therapy; polypharmacy; prevalence; psychotropic drugs

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE;

ADULT; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CINAHL; COMORBIDITY; DATA EXTRACTION; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDLINE; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCINFO; REVIEW; SYSTEMATIC REVIEW; ADOLESCENT; AUTISM SPECTRUM DISORDER; CLASSIFICATION; FEMALE; MALE;

ADOLESCENT; AUTISM SPECTRUM DISORDER; CHILD; FEMALE; HUMANS; MALE; POLYPHARMACY; PREVALENCE; PSYCHOTROPIC DRUGS;

EID: 84992560894     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12644     Document Type: Review

References (97)

1. Matson JL, Cervantes PE. Commonly studied comorbid psychopathologies among persons with autism spectrum disorder. Res Dev Disabil 2014;35:952–962.
2. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat Rev Neurol 2014;10:74–81.
3. Christensen DL, Baio J, Braun KVN et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years – autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ 2016;65:1–23.
4. Elsabbagh M, Divan G, Koh YJ et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res 2012;5:160–179.
5. Hansen SN, Schendel DE, Parner ET. Explaining the increase in the prevalence of autism spectrum disorders. JAMA Pediatr 2015;169:56.
6. Brugha T, Cooper S, McManus S et al. Estimating the Prevalence of Autism Spectrum Conditions in Adults: Extending the 2007 Adult Psychiatric Morbidity Survey, 2012. http://www.hscic.gov.uk/catalogue/PUB05061/esti-prev-auti-ext-07-psyc-morb-surv-qual.pdf
7. LeClerc S, Easley D. Pharmacological therapies for autism spectrum disorder: a review. PT 2015;40:389–397.
8. Volkmar F, Siegel M, Woodbury-Smith M, King B, McCracken J, State M. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2014;53:237–257.
9. Centers for Disease Control and Prevention (CDC). Autism Spectrum Disorder (ASD) – Treatment. http://www.cdc.gov/ncbddd/autism/treatment.html (Accessed 20 April 2016).
10. Höfer J, Hoffmann F, Bachmann C. Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: a systematic review. Autism 2016. doi:10.1177/1362361316646559. [Epub ahead of print]
11. Farmer C, Thurm A, Grant P. Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs 2013;73:303–314.
12. Poustka L, Kamp-Becker I. Current practice and future avenues in autism therapy. Current Topics in Behavioral Neurosciences. Berlin: Springer, 2016. Series ISSN 1866-3370.
13. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 2008;47:921–929.
14. Food and Drug Administration (FDA). FDA Approves the First Drug to Treat Irritability Associated with Autism, Risperdal, 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm (Accessed 26 February 2016).
15. ® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years). http://news.bms.com/press-release/rd-news/us-food-and-drug-administration-approves-abilify-aripiprazole-treatment-irrita (Accessed 19 April 2016).
16. Steckler T, Spooren W, Murphy D. Autism spectrum disorders-An emerging area in psychopharmacology. Psychopharmacology 2014;231:977–978.
17. Mire SS, Nowell KP, Kubiszyn T, Goin-Kochel RP. Psychotropic medication use among children with autism spectrum disorders within the Simons Simplex Collection: are core features of autism spectrum disorder related? Autism 2014;18:933–942.
18. Pearson DA, Santos CW, Aman MG et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol 2013;23:337–351.
19. Reichow B, Volkmar FR, Bloch MH. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord 2013;43:2435–2441.
20. Hurwitz R, Blackmore R, Hazell P, Williams K, Woolfenden S. Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database Syst Rev 2012;3:CD008372.
21. Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2013;8:CD004677.
22. McPheeters ML, Warren Z, Sathe N et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011;127:e1312–e1321.
23. Bachmann CJ, Lempp T, Glaeske G, Hoffmann F. Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012. Dtsch Arztebl Int 2014;111:25–34.
24. Merikangas KR, He J, Rapoport J, Vitiello B, Olfson M. Medication use in US youth with mental disorders. JAMA Pediatr 2013;167:141–148.
25. Olfson M, Blanco C, Liu S-M, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012;69:1–10.
26. Steinhausen HC, Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand 2014;129:221–231.
27. Toteja N, Gallego JA, Saito E et al. Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. Int J Neuropsychopharmacol 2014;17:1095–1105.
28. Akins RS, Krakowiak P, Angkustsiri K, Hertz-Picciotto I, Hansen RL. Utilization patterns of conventional and complementary/alternative treatments in children with autism spectrum disorders and developmental disabilities in a population-based study. J Dev Behav Pediatr 2014;35:1–10.
29. Aman MG, Lam KSL, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord 2003;33:527–534.
30. Aman MG, Van Bourgondien ME, Wolford PL, Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 1995;34:1672–1681.
31. Buck TR, Viskochil J, Farley M et al. Psychiatric comorbidity and medication use in adults with autism spectrum disorder. J Autism Dev Disord 2014;44:3063–3071.
32. Croen LA, Najjar DV, Ray GT, Lotspeich L, Bernal P. A comparison of health care utilization and costs of children with and without autism spectrum disorders in a large group-model health plan. Pediatrics 2006;118:e1203–e1211.
33. Esbensen AJ, Greenberg JS, Seltzer MM, Aman MG. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord 2009;39:1339–1349.
34. Frazier TW, Shattuck PT, Narendorf SC, Cooper BP, Wagner M, Spitznagel EL. Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21:571–579.
35. Hanson E, Kalish LA, Bunce E et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord 2007;37:628–636.
36. Hill AP, Zuckerman KE, Hagen AD et al. Aggressive behavior problems in children with autism spectrum disorders: prevalence and correlates in a large clinical sample. Res Autism Spectr Disord 2014;8:1121–1133.
37. House SA, Goodman DC, Weinstein SJ, Chang C-H, Wasserman JR, Morden NE. Prescription use among children with autism spectrum disorders in northern New England: intensity and small area variation. J Pediatr 2016;169:277–283.e2.
38. Khanna R, Jariwala K, West-Strum D. Use and cost of psychotropic drugs among recipients with autism in a state Medicaid fee-for-service programme. J Intellect Disabil Res 2013;57:161–171.
39. Langworthy-Lam KS, Aman MG, Van Bourgondien ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol 2002;12:311–321.
40. Liptak GS, Stuart T, Auinger P. Health care utilization and expenditures for children with autism: data from U.S. national samples. J Autism Dev Disord 2006;36:871–879.
41. Logan SL, Nicholas JS, Carpenter LA, King LB, Garrett-Mayer E, Charles JM. High prescription drug use and associated costs among medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network. Ann Epidemiol 2012;22:1–8.
42. Logan SL, Carpenter L, Leslie RS et al. Aberrant behaviors and co-occurring conditions as predictors of psychotropic polypharmacy among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 2015;25:323–336.
43. Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 2008;121:e441–e448.
44. Matone M, Localio R, Huang YS, Dosreis S, Feudtner C, Rubin D. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children. Health Serv Res 2012;47:1836–1860.
45. Nickels K, Katusic SK, Colligan RC, Weaver AL, Voigt RG, Barbaresi WJ. Stimulant medication treatment of target behaviors in children with autism: a population-based study. J Dev Behav Pediatr 2008;29:75–81.
46. Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 2007;17:348–355.
47. Rosenberg RE, Mandell DS, Farmer JE, Law JK, Marvin AR, Law PA. Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. J Autism Dev Disord 2010;40:342–351.
48. Schubart JR, Camacho F, Leslie D. Psychotropic medication trends among children and adolescents with autism spectrum disorder in the Medicaid program. Autism 2014;18:631–637.
49. Spencer D, Marshall J, Post B et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics 2013;132:833–840.
50. Stein BD, Sorbero MJ, Goswami U, Schuster J, Leslie DL. Impact of a private health insurance mandate on public sector autism service use in Pennsylvania. J Am Acad Child Adolesc Psychiatry 2012;51:771–779.
51. Sullivan AL, Sadeh S. Psychopharmacological treatment among adolescents with disabilities: prevalence and predictors in a nationally representative sample. Sch Psychol Q 2015;30:443–455.
52. Towle PO, Vacanti-Shova K, Shah S, Higgins-D'alessandro S. School-aged functioning of children diagnosed with autism spectrum disorder before age three: parent-reported diagnostic, adaptive, medication, and school placement outcomes. J Autism Dev Disord 2014;44:1357–1372.
53. Tsiouris A, Kim S-Y, Brown TW, Pettinger J, Cohen L. Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. J Autism Dev Disord 2013;43:719–731.
54. Tureck K, Matson JL, Turygin N, Macmillan K. Rates of psychotropic medication use in children with ASD compared to presence and severity of problem behaviors. Res Autism Spectr Disord 2013;7:1377–1382.
55. Williams PG, Woods C, Stevenson M, Davis DW, Radmacher P, Smith M. Psychotropic medication use in children with autism in the Kentucky Medicaid population. Clin Pediatr (Phila) 2012;51:923–927.
56. Witwer A, Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol 2005;15:671–681.
57. Zuckerman KE, Lindly OJ, Sinche BK, Nicolaidis C. Parent health beliefs, social determinants of health, and child health services utilization among U.S. school-age children with autism. J Dev Behav Pediatr 2015;36:146–157.
58. Rubin DM, Feudtner C, Localio R, Mandell DS. State variation in psychotropic medication use by foster care children with autism spectrum disorder. Pediatrics 2009;124:e305–e312.
59. Konstantareas M, Homatidis S, Cesaroni L. Brief report: variables related to parental choice to medicate their autistic children. J Autism Dev Disord 1995;25:443–452.
60. Lake JK, Weiss JA., Dergal J, Lunsky Y. Child, parent, and service predictors of psychotropic polypharmacy among adolescents and young adults with an autism spectrum disorder. J Child Adolesc Psychopharmacol 2014;24:486–493.
61. Mire SS, Raff NS, Brewton CM, Goin-Kochel RP. Age-related trends in treatment use for children with autism spectrum disorder. Res Autism Spectr Disord 2015;15–16:29–41.
62. Coury DL, Anagnostou E, Manning-Courtney P et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 2012;130(Suppl):S69–S76.
63. Gralton EJ, James DH, Lindsey MP. Antipsychotic medication, psychiatric diagnosis and children with intellectual disability: a 12-year follow-up study. J Intellect Disabil Res 1998;42(Pt 1):49–57.
64. Murray ML, Hsia Y, Glaser K et al. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology 2014;231:1011–1021.
65. Morgan CNR. Psychiatric comorbidity and medication use in autism: a community survey. Psychiatr Bull 2003;27:378–381.
66. Perumal N, Balan N, Stanfield A. Psychopharmacology in children with intellectual disability and autism—a cross-sectional analysis (2010). Int J Dev Disabil 2013;59:11–19.
67. Bachmann CJ, Manthey T, Kamp-Becker I, Glaeske G, Hoffmann F. Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Res Dev Disabil 2013;34:2551–2563.
68. Dalsgaard S, Nielsen HS, Simonsen M. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register. J Child Adolesc Psychopharmacol 2013;23:432–439.
69. Kielinen M, Linna SL, Moilanen I. Some aspects of treatment and habilitation of children and adolescents with autistic disorder in Northern-Finland. Int J Circumpolar Health 2002;61(Suppl 2):69–79.
70. Al-Salehi SM, Al-Hifthy EH, Ghaziuddin M. Autism in Saudi Arabia: presentation, clinical correlates and comorbidity. Transcult Psychiatry 2009;46:340–347.
71. Memari AH, Ziaee V, Beygi S, Moshayedi P, Mirfazeli FS. Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: perspective from a developing country. Res Dev Disabil 2012;33:563–569.
72. Louw K-A, Bentley J, Sorsdahl K, Adnams CM. Prevalence and patterns of medication use in children and adolescents with autism spectrum disorders in the Western Cape, South Africa. J Child Adolesc Ment Health 2013;25:69–79.
73. Goin-Kochel RP, Myers BJ, Mackintosh VH. Parental reports on the use of treatments and therapies for children with autism spectrum disorders. Res Autism Spectr Disord 2007;1:195–209.
74. Esbensen AJ, Seltzer MM, Lam KSL, Bodfish JW. Age-related differences in restricted repetitive behaviors in autism spectrum disorders. J Autism Dev Disord 2009;39:57–66.
75. Shattuck PT, Seltzer MM, Greenberg JS et al. Change in autism symptoms and maladaptive behaviors in adolescents and adults with an autism spectrum disorder. J Autism Dev Disord 2007;37:1735–1747.
76. Joshi G, Wozniak J, Petty C et al. Psychiatric comorbidity and functioning in a clinically referred population of adults with autism spectrum disorders: a comparative study. J Autism Dev Disord 2013;43:1314–1325.
77. Lever AG, Geurts HM. Psychiatric co-occurring symptoms and disorders in young, middle-aged, and older adults with autism spectrum disorder. J Autism Dev Disord 2016;46:1916–1930.
78. Ecker C. The neuroanatomy of autism spectrum disorder: an overview of structural neuroimaging findings and their translatability to the clinical setting. Autism 2016. doi: 10.1177/1362361315627136. [Epub ahead of print].
79. Kirkovski M, Enticott PG, Fitzgerald PB. A review of the role of female gender in autism spectrum disorders. J Autism Dev Disord 2013;43:2584–2603.
80. Park SY, Cervesi C, Galling B et al. Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: a meta-analysis. J Am Acad Child Adolesc Psychiatry 2016;55:456–468.e4.
81. Barnard L, Young AH, Pearson J, Geddes J, O'Brien G. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002;16:93–101.
82. National Institute for Health and Care Excellence (NICE). Autism spectrum disorder in under 19s: support and management. https://www.nice.org.uk/guidance/cg170/resources/autism-in-under-19s-support-and-management-35109745515205 (Accessed 12 August 2016).
83. National Institute for Health and Care Excellence (NICE). Autism in adults: diagnosis and management. https://www.nice.org.uk/guidance/cg142/resources/autism-in-adults-diagnosis-and-management-35109567475909 (Accessed 12 August 2016).
84. Zito JM, Safer DJ, de Jong-van den Berg LTW et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008;2:26.
85. Hsia Y, Wong AYS, Murphy DGM, Simonoff E, Buitelaar JK, Wong ICK. Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology 2014;231:999–1009.
86. Rani FA, Byrne PJ, Murray ML, Carter P, Wong ICK. Paediatric Atypical Antipsychotic Monitoring Safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings. Drug Saf 2009;32:325–333.
87. Briles JJ, Rosenberg DR, Brooks BA, Roberts MW, Diwadkar VA. Review of the safety of second-generation antipsychotics: are they really ‘Atypically’ safe for youth and adults? Prim Care Companion CNS Disord 2012;14:doi: 10.4088/PCC.11r0129810.4088/PCC.11r01298.
88. Lee W, Lee T, Pickard A, Caskey R, Schumock T. Drugs associated with adverse events in children and adolescents. Pharmacotherapy 2014;34:918–926.
89. Kaguelidou F, Acquaviva E. Safety of psychotropic drugs in children and adolescents. In: Edoardo S, Gianluca T, eds. Pharmacovigilance in psychiatry. Cham, Switzerland: Springer International Publishing, 2016: 257–283.
90. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011;26:144–158.
91. Nicolaidis C, Kripke CC, Raymaker D. Primary care for adults on the autism spectrum. Med Clin North Am 2014;98:1169–1191.
92. Clavenna A, Bonati M. Safety and tolerability of medications for ADHD. In: Edoardo S, Gianluca T, eds. Pharmacovigilance in psychiatry. Cham, Switzerland: Springer International Publishing, 2016, 233–253.
93. Gören JL, Tewksbury A. Drug interactions and polypharmacy. In: Michael SR, ed. Polypharmacy in psychiatry practice, Vol. I. Dordrecht: Springer Netherlands, 2013, 45–74.
94. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012;11:527–542.
95. Jureidini J, Tonkin A, Jureidini E. Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs. Pediatr Drugs 2013;15:377–391.
96. Weitlauf AS, McPheeters ML, Peters B et al. Therapies for Children with Autism Spectrum Disorder: Behavioral Interventions Update. AHRQ Publ No 14-EHC036-EF Rockville, MD Agency Healthc Res Qual 2014:120.
97. Matson JL, Jang J. Treating aggression in persons with autism spectrum disorders: a review. Res Dev Disabil 2014;35:3386–3391.